Special Issue

Stereotactic Body Radiotherapy

Message from the Guest Editor

Stereotactic radiotherapy (SRT) is a treatment option curing cancer that creates highly conformal dose distributions with steep dose gradients, using advanced planning and treatment equipment. Stereotactic radiotherapy allows for the safe delivery of high doses of radiation to the target lesion, while sparing the surrounding critical organs. More specifically, in clinical practice, it is a useful tool in patients affected by limited metastatic disease, defined as an “oligometastatic state”, which is considered as an intermediate state between localized and widespread cancer. In patients with a limited number of metastases from a variety of primary sites, it seems that SRT might improve overall survival and disease-progression-free survival, with a limited cost in terms of treatment-related morbidity. SRT is also under investigation for the treatment of primary tumors, instead of surgery or conventional radiotherapy, such as for curing lung cancer and prostate cancer. For these reasons, this Special Issue will explore the use of stereotactic radiotherapy in the therapy of solid tumors.

Guest Editor

Dr. Gianluca Ingrosso

Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy

Deadline for manuscript submissions

closed (10 September 2021)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/51534

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).